PBPK modeling of irbesartan: incorporation of hepatic uptake

Physiological based pharmacokinetic (PBPK) modeling is now commonly used in drug development to integrate human or animal physiological data in order to predict pharmacokinetic profiles. The aim of this work was to construct and refine a PBPK model of irbesartan taking into account its active uptake via OATP1B1/B3 in order to predict more accurately its pharmacokinetic profile using Simcyp^®. The activity and expression of the human hepatocyte transporters OATP1B1 and OATP1B3 were studied. The relative activity factors (RAFs) for OATP1B1 and OATP1B3 transporters were calculated from intrinsic clearances obtained by concentration dependent uptake experiments in human hepatocytes and HEK overexpressing cells: RAF_1B1 using estrone‐3‐sulfate and pitavastatine clearances, and RAF_1B3 using cholecystokinine octapeptide (CCK‐8) clearances. The relative expression factor (REF) was calculated by comparing immunoblotting of hepatocytes (REF_HH) or tissues (REF_tissue) with those of overexpressing HEK cells for each transporter. These scaling factors were applied in a PBPK model of irbesartan using the Simcyp® simulator. Pharmacokinetic simulation using REF_HH (1.82 for OATP1B1, 8.03 for OATP1B3) as an extrapolation factor was the closest to the human clinical pharmacokinetic profile of irbesartan. These investigations show the importance of integrating the contribution of the active uptake of a drug in the liver to improve PBPK modeling. Copyright © 2015 John Wiley & Sons, Ltd.     

Fentanyl Pharmacokinetics is not Dependent on Hepatic Uptake by Organic Anion‐Transporting Polypeptide 1B1 in Human Beings

A recent study investigating the pharmacokinetics of fentanyl in Sprague–Dawley rats suggested fentanyl to be a substrate of rat organic anion‐transporting polypeptide Oatp. In human beings, the most important OATP for the pharmacokinetics of many drugs is OATP1B1. Therefore, genetic variants of OATP1B1 (SLCO1B1) might modulate fentanyl pharmacokinetics and efficacy in human beings. Sixteen healthy male and female volunteers, homozygous for SLCO1B1*1a (genetic wild‐type) (n = 11) or *15 (deficient haplotype carrying the single‐nucleotide polymorphisms rs2306283 and rs4149056 and exhibiting altered transport activity; n = 5), were included in this randomized crossover study. The participants received fentanyl (5 μg/kg) intravenously alone or with the OATP inhibitor rifampicin (600 mg single oral dose). The pharmacokinetics of fentanyl and norfentanyl were determined by liquid chromatography coupled to tandem mass spectrometry (LC‐MS/MS). In addition, fentanyl uptake in vitro was evaluated in OATP1B1 overexpressing HEK293 cells and compared to a mock‐transfected cell line. In the clinical trial, fentanyl clearance was 18.8 ± 8.2 mL/min. kg in SLCO1B1*1a and 19.5 ± 1.8 mL/min/kg in SLCO1B1*15 carriers and not significantly different between the genotypes. During rifampicin, fentanyl clearance was 15.0 ± 4.4 mL/min/kg in SLCO1B1*1a and 16.7 ± 5.9 mL/min/kg in SLCO1B1*15 carriers (p > 0.5). In addition, in vitro data also indicate that fentanyl is not transported by OATP1B1. In conclusion, our data indicate that OATP1B1 has no impact on fentanyl pharmacokinetics in human beings.     

Characterization of Hepatobiliary Transport Systems of a Novel α4β1/α4β7 Dual Antagonist, TR-14035

Purpose Our previous pharmacokinetic studies have demonstrated that TR-14035, a novel dual antagonist for α4β1/α4β7 integrin, selectively and strongly accumulated in the liver and was mainly excreted in bile as an unchanged drug. In the present study, we investigated the hepatobiliary transport system in detail.Materials and Methods Uptake by hepatocytes and organic anion transporting polypeptide (OATP)-expressing Xenopus laevis oocytes or Flp-In-293 cells was performed in vitro. Biliary excretion was investigated in mdr1a/b-knockout mice, Bcrp-knockout mice and Mrp2-defective Eisai hyperbilirubinemic rats (EHBRs).Results TR-14035 was taken up by rat and human hepatocytes by an apparently single saturable mechanism with K _m of 6.7 and 2.1 μM, respectively, and taurocholate and digoxin reduced this uptake. OATP1B1/OATP-C and OATP1B3/OATP8 expressed in oocytes mediated the TR-14035 uptake with K _m of 7.5 and 5.3 μM, respectively. OATP1B1*15, a genetic variant of OATP1B1, exhibited a decreased transport of TR-14035 compared with OATP1B1*1a. Biliary excretion and total body clearance of unchanged TR-14035 in EHBRs were significantly lower than those in normal rats, while there was no difference in the clearances between wild and mdr1a/b- or Bcrp-knockout mice.Conclusion These results indicate that OATP1B1 and OATP1B3 are at least partly responsible for the accumulation of TR-14035 into hepatocytes, and Mrp2 principally mediates the biliary excretion of TR-14035. Furthermore, genetic polymorphisms of OATP1B1 may cause an interindividual variability in the pharmacokinetics of TR-14035.     

Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats

The present study aimed to examine the potential pharmacokinetic drug interaction between valsartan and gemfibrozil. Compared with the control given valsartan (10 mg/kg) alone, the concurrent use of gemfibrozil (10 mg/kg) significantly (p < 0.05) increased the oral exposure of valsartan in rats. In the presence of gemfibrozil, the C_max and AUC of oral valsartan increased by 1.7‐ and 2.5‐fold, respectively. Consequently, the oral bioavailability of valsartan was significantly higher (p < 0.05) in the presence of gemfibrozil compared with that of the control group. Furthermore, the intravenous pharmacokinetics of valsartan (1 mg/kg) was also altered by pretreatment with oral gemfibrozil (10 mg/kg). The plasma clearance of valsartan was decreased by two‐fold in the presence of gemfibrozil, while the plasma half‐life was not altered. In contrast, both the oral and intravenous pharmacokinetics of gemfibrozil were not affected by the concurrent use of valsartan. The cellular uptake of valsartan and gemfibrozil was also investigated by using cells overexpressing OATP1B1 or OATP1B3. Gemfibrozil and gemfibrozil 1‐O‐β glucuronide inhibited the cellular uptake of valsartan with IC₅₀ values (µm ) of 39.3 and 20.4, respectively, in MDCK/OATP1B1, while they were less interactive with OATP1B3. The cellular uptake of gemfibrozil was not affected by co‐incubation with valsartan in both cells. Taken together, the present study suggests the potential drug interaction between valsartan and gemfibrozil, at least in part, via the OATP1B1‐mediated transport pathways during hepatic uptake. Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.     

Prediction of Human Pharmacokinetics from Preclinical Information of Rhein,an Antidiabetic Nephropathy Drug,Using a Physiologically Based Pharmacokinetic Model

The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model of rhein to predict human pharmacokinetics before dosing for the first time in human beings. After oral administration of rhein at the doses of 35, 70 and 140 mg/kg in rat, rhein had the following mean plasma pharmacokinetic properties: t_1/2 of 3.2, 3.6 and 4.3 hr, AUC_∞ of 69.5, 164.3 and 237.8 μg/h/ml and CL/F of 503.4, 426.1 and 588.8 ml/hr/kg, respectively. In vitro, the intrinsic clearance (Cl_int) of rhein in cytochrome P450 (CYP450), UDP‐glucuronosyltransferase (UGT) and sulfotransferase (SULT) metabolism of rat was 0.6, 7.8, and 5.5 μl/min/mg protein, respectively. The Cl_int of rhein in CYP450, UGT and SULT of human beings was 0.10, 1.36 and 0.68 μl/min/mg protein. The rat pharmacokinetics and the metabolism data in vitro were used to construct the PBPK model of rhein, and the observed plasma drug concentration profiles of rhein in rat were validated by a PBPK model. Subsequently, the plasma drug concentration profiles of human beings by the present PBPK model were validated by experimental data in human beings accurately.     

Organic anion-transporting polypeptide (OATP) 2B1 contributes to the cellular uptake of theaflavin

Organic anion-transporting polypeptide (OATP) 2B1 has been reported in the apical membranes of the human small intestinal epithelium, where it contributes to the intestinal absorption of pharmacologically active drugs. To investigate the potential for OATP2B1-mediated drug–food interactions, the effects of several polyphenolic compounds on OATP2B1-mediated estrone-3-sulfate (E3S) transport were studied by using OATP2B1-expressing HEK293 cells. Our results showed that some compounds, especially theaflavin, were strong inhibitors of OATP2B1-mediated E3S uptake. Theaflavin showed a significantly higher uptake into the OATP2B1-expressing HEK293 cells than the control cells. The concentration dependence of the uptake of theaflavin was determined over a range of concentrations (0.5–100 μM) and the kinetic parameters (K_m and V_max) of theaflavin uptake were found to be 5.12 ± 0.67 μM and 41.6 ± 1.3 pmol/mg protein/min, respectively. The OATP2B1-mediated theaflavin uptake was inhibited by known OATP2B1 substrates such as E3S, bromsulphthalein (BSP), dehydroepiandrosterone-3-sulfate (DHEAS), and fluvastatin. Our results indicate that theaflavin is a novel substrate of OATP2B1. The results of this study might be helpful to predict the potential OATP2B1-mediated drug–theaflavin interactions and to avoid undesirable clinical consequences.     

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

With efforts to reduce cytochrome P450-mediated clearance (CL) during the early stages of drug discovery, transporter-mediated CL mechanisms are becoming more prevalent. However, the prediction of plasma concentration-time profiles for such compounds using physiologically based pharmacokinetic (PBPK) modeling is far less established in comparison with that for compounds with passively mediated pharmacokinetics (PK). In this study, we have assessed the predictability of human PK for seven organic anion-transporting polypeptide (OATP) substrates (pravastatin, cerivastatin, bosentan, fluvastatin, rosuvastatin, valsartan, and repaglinide) for which clinical intravenous data were available. In vitro data generated from the sandwich culture human hepatocyte system were simultaneously fit to estimate parameters describing both uptake and biliary efflux. Use of scaled active uptake, passive distribution, and biliary efflux parameters as inputs into a PBPK model resulted in the overprediction of exposure for all seven drugs investigated, with the exception of pravastatin. Therefore, fitting of in vivo data for each individual drug in the dataset was performed to establish empirical scaling factors to accurately capture their plasma concentration-time profiles. Overall, active uptake and biliary efflux were under- and overpredicted, leading to average empirical scaling factors of 58 and 0.061, respectively; passive diffusion required no scaling factor. This study illustrates the mechanistic and model-driven application of in vitro uptake and efflux data for human PK prediction for OATP substrates. A particular advantage is the ability to capture the multiphasic plasma concentration-time profiles for such compounds using only preclinical data. A prediction strategy for novel OATP substrates is discussed.     

Heavy metal influence on BDE‐47 uptake in the human KERTr keratinocyte cell line

Significant correlations between concentrations of PBDEs and heavy metals were observed in the human body. However, there is a lack of evidence on the linkage between the uptake of heavy metals and PBDEs. This study is the first report on the BDE‐47 uptake profile in a human cell line. Hg and As exposures to KERTr (human skin derived keratinocyte) did not significantly (p > 0.05) affect the uptake of BDE47, whereas Pb and Cd significantly (p < 0.05) affected the uptake of BDE‐47 in KERTr. The change in K_m was minor after exposure to all heavy metals. The maximum transport rate (V_max) after exposure to Pb (V_max: 5.23 ± 0.49) and As (V_max: 4.95 ± 0.60) was significantly increased when compared with the background of the KERTr cell line (V_max: 4.07 ± 0.35). Real‐time RT‐PCR indicated that OATP‐B, OATP‐D, and OATP‐E were expressed in the KERTr cell line. The upregulation or downregulation of OATP B and D genes were minor after exposure to heavy metals, but the OATP E gene was upregulated by three to fourfold in KERTr cell line after exposure to Pb an Cd, which may explain the significant increase of uptake of BDE‐47 in KERTr after exposures to Pb and Cd. This study indicated that the uptake effects should be considered when performing risk assessment of human exposure to PBDEs and heavy metal. © 2013 Wiley Periodicals, Inc. Environ Toxicol 29: 354–361, 2014.     

Are organic cation transporters capable of transporting prostaglandins?

The non-neuronal monoamine transporters OCT1, OCT2 and EMT (human gene symbols SLC22A1-A3) efficiently transport a number of positively-charged monoamines and some small organic cations across the plasma membrane, and thus are implicated in the inactivation of released monoamine transmitters (e.g. noradrenaline, histamine, agmatine) in vivo. Although prostaglandins are full anions at physiological pH, data from a recent publication suggest efficient transport of the prostaglandins PGE₂ and by OCT1 and OCT2. In the present study we have reexamined transport of PGE₂ by OCT2 from human (OCT2h). Uptake of substrate into monolayers of 293 cells, stably transfected to express OCT2h, was compared to uptake into non-transfected control cells. Efficiency of transport of the established substrate ³H-1-methyl-4-phenylpyridinium (MPP⁺), expressed as clearance, was high at 81 μl min⁻¹ mg protein⁻¹ on average. By contrast, uptake of ³H-PGE₂ was virtually identical for control cells and OCT2h cells. The efficiency of transport was 0.1±0.6, 1.0±0.3, and 0.7±0.4 μl min⁻¹ mg protein⁻¹ for cell lysis with methanol, HClO₄, and Triton X-100 respectively. Similar results were obtained with unlabeled MPP⁺ (192±12 μl min⁻¹ mg protein⁻¹) and PGE₂ (0.3±0.1 μl min⁻¹ mg protein⁻¹) in LC-MS/MS analysis. We conclude that OCT2h is not capable of transporting prostaglandins. The data from the previous report may represent binding rather than transport. Our comparison of transport efficiencies confirms the notion that relevant substrates of OCT1, OCT2, and EMT must carry a positive charge. Supported by Deutsche Forschungsgemeinschaft (SCHO 373/4-1)     

In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives

Hepatocyte uptake of phalloidin is carried out mainly by OATP1B1. We have used this compound as a prototypic substrate and assayed the ability to inhibit OATP-mediated phalloidin transport of four bile acid derivatives (BALU-1, BALU-2, BALU-3 and BALU-4) that showed positive results in preliminary screening. Using Xenopus laevis oocytes for heterologous expression of transporters, BALUs were found to inhibit taurocholic acid (TCA) transport by OATP1B1 (but not OATP1B3) as well as by rat Oatp1a1, Oatp1a4 and Oatp1b2. The study of their ability to inhibit sodium-dependent bile acid transporters revealed that the four BALUs induced an inhibition of rat Asbt-mediated TCA transport, which was similar to TCA-induced self-inhibition. Regarding human NTCP and rat Ntcp, BALU-1 differs from the other three BALUS in its lack of effect on TCA transport by these proteins. Using HPLC–MS/MS and CHO cells stably expressing OATP1B1 the ability of BALU-1 to inhibit the uptake of phalloidin itself by this transporter was confirmed. Kinetic analysis using X. laevis oocytes revealed that BALU-1-induced inhibition of OATP1B1 was mainly due to a competitive mechanism (Ki = 8 μM). In conclusion, BALU-1 may be useful as a pharmacological tool to inhibit the uptake of compounds mainly taken up by OATP1B1 presumably without impairing bile acid uptake by the major carrier accounting for this process, i.e., NTCP.     

Prepubertal exposure to commercial formulation of the herbicide glyphosate alters testosterone levels and testicular morphology

Glyphosate is a herbicide widely used to kill weeds both in agricultural and non-agricultural landscapes. Its reproductive toxicity is related to the inhibition of a StAR protein and an aromatase enzyme, which causes an in vitro reduction in testosterone and estradiol synthesis. Studies in vivo about this herbicide effects in prepubertal Wistar rats reproductive development were not performed at this moment. Evaluations included the progression of puberty, body development, the hormonal production of testosterone, estradiol and corticosterone, and the morphology of the testis. Results showed that the herbicide (1) significantly changed the progression of puberty in a dose-dependent manner; (2) reduced the testosterone production, in semineferous tubules’ morphology, decreased significantly the epithelium height (P < 0.001; control = 85.8 ± 2.8 μm; 5 mg/kg = 71.9 ± 5.3 μm; 50 mg/kg = 69.1 ± 1.7 μm; 250 mg/kg = 65.2 ± 1.3 μm) and increased the luminal diameter (P < 0.01; control = 94.0 ± 5.7 μm; 5 mg/kg = 116.6 ± 6.6 μm; 50 mg/kg = 114.3 ± 3.1 μm; 250 mg/kg = 130.3 ± 4.8 μm); (4) no difference in tubular diameter was observed; and (5) relative to the controls, no differences in serum corticosterone or estradiol levels were detected, but the concentrations of testosterone serum were lower in all treated groups (P < 0.001; control = 154.5 ± 12.9 ng/dL; 5 mg/kg = 108.6 ± 19.6 ng/dL; 50 mg/dL = 84.5 ± 12.2 ng/dL; 250 mg/kg = 76.9 ± 14.2 ng/dL). These results suggest that commercial formulation of glyphosate is a potent endocrine disruptor in vivo, causing disturbances in the reproductive development of rats when the exposure was performed during the puberty period.     

Concentration-Dependent Effect of Naringin on Intestinal Absorption of β<Subscript>1</Subscript>-Adrenoceptor Antagonist Talinolol Mediated by P-Glycoprotein and Organic Anion Transporting Polypeptide (Oatp)

Purpose  The purpose of this study is to clarify the impact of P-gp and Oatp on intestinal absorption of the β₁-adrenoceptor antagonist talinolol. Methods  P-gp-mediated transport was measured in LLC-PK1/MDR1 cells. Oatp-mediated uptake was evaluated with Xenopus oocytes expressing Oatp1a5. Rat intestinal permeability was measured by the in situ closed loop method. In vivo absorption was pharmacokinetically assessed by measuring plasma concentration after oral administration in rats. Results  In LLC-PK1/MDR1 cells, the permeability of talinolol was markedly higher in the secretory direction than in the absorptive one. The uptake of talinolol by Xenopus oocytes expressing Oatp1a5 was significantly increased compared with that by water-injected oocytes. Naringin inhibited talinolol uptake by Oatp1a5 (IC ₅₀ = 12.7 μM). The reported IC ₅₀ value of naringin for P-gp-mediated transport of talinolol is approximately 2,000 μM. Rat intestinal permeability of talinolol was significantly decreased in the presence of 200 μM naringin, but was significantly increased by 2,000 μM naringin. Similar results were obtained in in vivo absorption studies in rats. Conclusion  The absorption behavior of talinolol can be explained by the involvement of both P-gp and Oatp, based on characterization of talinolol transport by Oatp1a5 and P-gp, and the effects of naringin.     

Transport properties of valsartan,sacubitril and its active metabolite (LBQ657) as determinants of disposition

1.?The potential for drug–drug interactions of LCZ696 (a novel, crystalline complex comprising sacubitril and valsartan) was investigated in vitro.

2.?Sacubitril was shown to be a highly permeable P-glycoprotein (P-gp) substrate and was hydrolyzed to the active anionic metabolite LBQ657 by human carboxylesterase 1 (CES1b and 1c). The multidrug resistance-associated protein 2 (MRP2) was shown to be capable of LBQ657 and valsartan transport that contributes to the elimination of either compound.

3.?LBQ657 and valsartan were transported by OAT1, OAT3, OATP1B1 and OATP1B3, whereas no OAT- or OATP-mediated sacubitril transport was observed.

4.?The contribution of OATP1B3 to valsartan transport (73%) was appreciably higher than that by OATP1B1 (27%), Alternatively, OATP1B1 contribution to the hepatic uptake of LBQ657 (～70%) was higher than that by OATP1B3 (～30%).

5.?None of the compounds inhibited OCT1/OCT2, MATE1/MATE2-K, P-gp, or BCRP. Sacubitril and LBQ657 inhibited OAT3 but not OAT1, and valsartan inhibited the activity of both OAT1 and OAT3. Sacubitril and valsartan inhibited OATP1B1 and OATP1B3, whereas LBQ657 weakly inhibited OATP1B1 but not OATP1B3.

6.?Drug interactions due to the inhibition of transporters are unlikely due to the redundancy of the available transport pathways (LBQ657: OATP1B1/OAT1/3 and valsartan: OATP1B3/OAT1/3) and the low therapeutic concentration of the LCZ696 analytes.     

Species specificity profiling of rat and human organic cation/carnitine transporter Slc22a5/SLC22A5 (Octn2/OCTN2)

The purpose of this study was to characterize the uptake of carnitine, the physiological substrate, and the uptake of 3-(2,2,2-trimethylhydrazinium)propionate, a consensus substrate by rat Octn2 and human OCTN2 transporters as well as to characterize drug-mediated inhibition of l-carnitine uptake by the rat and human orthologs overexpressed in CHO-K1 cells. l-carnitine and 3-(2,2,2-trimethylhydrazinium)propionate were found to be a lower affinity substrate for rat Octn2 (K_M = 32.66 ± 5.11 μM and 23.62 ± 4.99 μM respectively) than for human OCTN2 (K_M = 3.08 ± 0.74 μM and 7.98 ± 0.63 μM). The intrinsic clearance (CL_int) value for carnitine was higher for the human than for the rat transporter (22.82 ± 5.57 ml/min*mg vs 4.008 ± 0.675 ml/min*mg). For 3-(2,2,2-trimethylhydrazinium)propionate, in contrast, the CL_int value for rat Octn2 was higher than for human OCTN2 (323.9 ± 72.8 ml/min*mg vs 65.11 ± 5.33 ml/min*mg).Furthermore, many pharmacologically important drugs were shown to affect l-carnitine transport by Octn2/OCTN2. The correlation between the IC₅₀ datasets for the rat and human transporter resulted in an r value of 0.47 (p > 0.05). However, the greatest difference was less than seven-fold and 13 of 15 compounds yielded a difference less than 3-fold.Thus, the transporters from these two species showed an overlapping but somewhat different substrate and inhibitor specificity.     

Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5

Rationale Cyp2a5, the mouse homologue of human CYP2A6, encodes for the enzyme responsible for the primary metabolism of nicotine. Variation in human CYP2A6 activity can alter the amount smoked such as number of cigarettes smoked per day and smoking intensity. Different mouse strains self-administer different amounts of oral nicotine and quantitative trait loci analyses in mice suggested that Cyp2a5 may be involved in differential nicotine consumption behaviors. Objectives The goal of this study was to examine whether in vivo nicotine consumption levels were associated with CYP2A5 protein levels and in vitro nicotine metabolism in mice. Methods F2 mice propagated from high (C57Bl/6) and low (St/bJ) nicotine consuming mice were analyzed for CYP2A5 hepatic protein levels and in vitro nicotine metabolizing activity. Results We found that F2 male high-nicotine (n=8; 25.1±1.2 μg nicotine/day) consumers had more CYP2A5 protein, compared to low (n=11; 3.8±1.4 μg nicotine/day) consumers (10.2±1.0 vs 6.5±1.3 CYP2A5 units). High consumers also metabolized nicotine faster than the low consumers (6 μM: 0.18±0.04 vs 0.14±0.07; 30 μM: 0.36± 0.06 vs 0.26±0.13; 60 μM: 0.49±0.05 vs 0.32±0.17 nmol/min/mg). In contrast, female high- (25.1±2.1 μg nicotine/day) and low-nicotine (4.7±1.4 μg nicotine/day) consumers did not show pronounced differences in nicotine metabolism or CYP2A4/5 protein levels; this is consistent with other studies of sex differences in response to nicotine. Conclusions These data suggested that among male F2 mice, increased nicotine self-administration is associated with increased rates of nicotine metabolism, most likely, as a result of greater CYP2A5 protein levels. This study was supported by CAMH, CIHR 14173 & 53248, CIHR–Special Training Program in Tobacco Use in Special Populations and Ontario Graduate Scholarship (ECKS) and a Canada Research Chair in Pharmacogenetics (RFT).     

Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system

Pretreatment of the G-protein coupled nociceptin receptor (NOP) with nociceptin/orphaninFQ (N/OFQ) produces desensitisation. The influences of receptor expression and genomic effects are largely unknown. We have used an ecdysone-inducible NOP expression system in a CHO line (CHO_INDhNOP) to examine the effects of N/OFQ pretreatment upon receptor density, GTPγ[³⁵S] binding, cAMP formation and NOP-mRNA. CHO_INDhNOP induced with 5 and 10 μM PonasteroneA (PonA) for 20 h produced NOP densities (B _max) of 194 and 473 fmol. mg^-1 protein, respectively. This was accompanied by decreased NOP mRNA. The lower B _max is typical of the central nervous system. Pretreatment with 1 μM N/OFQ significantly (p < 0.05) reduced B _max at 5 and 10 μM PonA to 100 and 196 fmol. mg^-1 protein, respectively. There was no change in binding affinity. Along with the reduction in B _max, potency and efficacy for N/OFQ-stimulated GTPγ[³⁵S] binding were also reduced (5 μM PonA: pEC₅₀-control = 8.55 ± 0.06, pretreated = 7.88 ± 0.07; E _max-control = 3.52 ± 0.43, pretreated = 2.48 ± 0.10; 10 μM PonA: pEC₅₀-control = 8.41 ± 0.18, pretreated = 7.76 ± 0.03; E _max-control = 5.07 ± 0.17, pretreated = 3.38 ± 0.19). For inhibition of cAMP formation, there was a reduction in potency (5 μM PonA: pEC₅₀-control = 9.78 ± 0.08, pretreated = 8.92 ± 0.13; 10 μM PonA: pEC₅₀-control = 9.99 ± 0.07, pretreated = 9.04 ± 0.14), but there was no reduction in efficacy. In addition, there were 39 and 31% reductions in NOP mRNA at 5 and 10 μM PonA, respectively, but these measurements were made following concurrent N/OFQ challenge and PonA induction. In CHO_INDhNOP, we have shown a reduction in cell surface receptor numbers and a reduction in functional coupling after N/OFQ pretreatment. This was observed at pseudo-physiological and supraphysiological receptor densities. Moreover, we also report a reduction in NOP mRNA, but further studies are needed which include ‘pulsing’ PonA and desensitizing following wash-out.     

α2C-Adrenoceptors mediate contractile responses to noradrenaline in the human saphenous vein

We have investigated the subtype of α₂-adrenoceptor mediating isometric contractions of human saphenous vein in comparison with α₂-adrenoceptor ligand binding sites. Postjunctional α₂-adrenoceptors in the human saphenous vein were investigated in terms of the ability of α₂-adrenoceptor antagonists to shift the contractile potency of noradrenaline. The following antagonists were employed (potencies, pKB, in human saphenous vein in parentheses): chlorpromazine (6.98±0.24), BDF 8933 (7.60±0.06), prazosin (6.62±0.15), ARC 239 (7.19±0.15), yohimbine (7.23±0.09), HV 723 (7.52±0.14), WB 4101 (7.90±0.06), SKF 104078 (6.55±0.08), BRL 44408 (5.72±0.21). Antagonist potency at postjunctional α₂-adrenoceptors was correlated with antagonist affinity at α₂-adrenoceptor ligand binding sites in membranes of human platelet (α_2A), rat kidney (α_2B) and Sf9 cells expressing human recombinant receptors (α_2C), labelled with [³H]yohimbine. The correlation with the postjunctional α₂-adrenoceptor mediating contraction of the human saphenous vein was best for the human recombinant α_2C-adrenoceptor ligand binding site (r=0.92, n=8, P<0.001), as compared to correlations with the α_2B-adrenoceptor ligand binding site of rat kidney (r=0.62, n=8, n.s.) and with the α_2A-adrenoceptor ligand binding site of human platelet (r=0.23, n=8, n.s.). It is concluded that the functional postjunctional α₂-adrenoceptor mediating contractions of the human saphenous vein closely resembles the human recombinant α_2C-adrenoceptor ligand binding site. Received: 23 September 1996 / Accepted: 3 December 1996     

齐墩果酸对OATP1B1介导药物转运功能的关联性影响

目的 探讨齐墩果酸对有机阴离子转运多肽1B1（organic anion transporting polypetide1B1,OATP1B1）转运功能的关联性影响。方法 利用稳定表达人OATP1B1的人胚胎肾293（hunan embyonic kindney293,HEK293）细胞株,以氟伐他汀为底物进行OATP1B1摄取反应,观察齐墩果酸对OATP1B1摄取功能的影响。结果 齐墩果酸对OATP1B1摄取氟伐他汀的功能有竞争性抑制作用,抑制常数Ki值为（20.3±2.1）mmol·L^-1。结论 齐墩果酸对肝脏药物转运体OATP1B1转运抑制作用可诱导中西药相互作用。